The burden of LC-MASLD has significantly increased, especially in economically disadvantaged countries.

SGLT2 inhibitors appeared effective in improving hepatic inflammation and fibrosis indices in patients with type 2 diabetes and suspected MASLD.

This analysis may help identify at-risk patients of liver enzyme elevation following sustained virologic response among individuals with hepatitis C virus infection.

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

A new study highlights suboptimal HDV screening rates in HBV-infected individuals, suggesting that treating HBV may improve survival for those with HDV coinfection.

Study findings showed children with both obesity and MASLD have a greater risk of youth-onset type 2 diabetes than those with obesity alone.

Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.

Anemia could be a reliable sign of all-cause mortality in patients with heart failure.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

In this analysis, the investigators sought to assess the efficacy and safety of risankizumab compared to placebo for patients with palmoplantar psoriasis.

A study found that migraine-related disability worsens health-related quality of life, with gender-specific differences, particularly affecting women with mild disability.

Patients with IBD or arthritis were not found to be at a significantly higher risk of serious infection with a biosimilar versus originator of the common drugs.

Linaclotide was safe and effective for patients with chronic constipation and IBS with constipation who switched after non-response to magnesium oxide.

These data resulted from comparisons of the time to onset of action among various available systemic medications for those with plaque psoriasis.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

A systematic review found cognitive impairment a defining characteristic of SCA, with a notable impact on individuals of all ages.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

This online diagnostic tool’s implementation among study participants led to increased confidence in making diagnoses of chronic plaque psoriasis.

The ustekinumab biosimilar will be available in early 2025, with indications to treat psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.

Phase 3 data found 66.5% of people with migraine attacks treated with STS101 had headache pain relief two hours after the dose.

In focus groups, patients indicated symptom bothersomeness and life interference should be included in clinical evaluation for disorders of gut-brain interaction.